T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

NOTCH1 pathway activation contributes to the pathogenesis of over 60% of T-cell acute lymphoblastic leukemia (T-ALL). While Notch is thought to exert the majority of its effects through ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell lymphoma.

Seven-year-old WA boy Ace was diagnosed with Acute Lymphoblastic Leukemia when he was just five years old. Acute lymphoblastic leukemia (ALL) is a type of blood cancer that occurs when the bone marrow ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its ...

Barrett told his grandma Honey, also known as Jill Lee, about the idea.

The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...